破裂性腹主动脉瘤开放与腔内修复的长期人群结局
基于加拿大安大略省2003至2016年行政数据的回顾性队列研究,纳入2692例40岁以上接受开放手术或腔内修复的破裂性腹主动脉瘤患者。经倾向评分加权后,腔内修复组在术后30天内全因死亡和主要不良心血管事件风险显著低于开放手术组,但30天至10年中期及长期无显著差异。
要点
- 腔内修复在破裂性腹主动脉瘤术后30天内全因死亡风险更低(HR 0.49)。
- 腔内修复在术后30天内主要不良心血管事件风险更低(HR 0.51)。
- 30天至10年中期及长期死亡和主要不良心血管事件风险无显著差异。
核心结论
- 腔内修复较开放手术降低破裂性腹主动脉瘤术后30天内全因死亡和主要不良心血管事件风险。
- 两种修复方式在30天至10年的中期及长期死亡和主要不良心血管事件风险无显著差异。
- 腔内修复的早期死亡和主要不良心血管事件获益持续超过术后4.5年。
研究设计与样本
- 研究为基于加拿大安大略省行政数据的回顾性人群队列研究。
- 纳入2003年4月1日至2016年3月31日期间40岁及以上接受开放手术或腔内修复的破裂性腹主动脉瘤患者2692例。
- 采用倾向评分逆概率加权和Cox比例风险回归分析。
主要发现
- 全队列2692例中,腔内修复261例(10%),开放手术2431例(90%)。
- 全队列平均随访3.4年(标准差3.9年),最长随访14.0年;开放手术组平均3.5年(标准差4.0年),腔内修复组平均2.7年(标准差2.7年)。
- 全队列中位生存期2.7年,开放手术组2.5年,腔内修复组3.7年。
- 30天至5年及5至10年,两组全因死亡和主要不良心血管事件风险无统计学显著差异。
临床怎么用
- 对于破裂性腹主动脉瘤,腔内修复可能降低术后30天内死亡和主要不良心血管事件风险。
- 选择修复方式时需权衡早期获益与中远期结局,腔内修复的中远期优势不显著。
局限性
- 研究基于行政数据,可能存在编码偏倚和未测量混杂。
- 腔内修复组样本量较小(261例)且随访时间较短(平均2.7年)。
- 研究为回顾性设计,结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Existing data regarding endovascular aortic repair (EVAR) of ruptured abdominal aortic aneurysm (rAAA) are conflicting in their findings. The purpose of this paper was to determine the long-term outcomes of EVAR vs open surgical repair (OSR) for treatment of rAAA. METHODS: A population-based retrospective cohort study of all patients 40 years or more that underwent OSR or EVAR of rAAA in Ontario, Canada, from 2003 to 2016 was conducted. Administrative data from the province of Ontario was used as the data source. The propensity for repair approach was calculated using a logistic regression model including all covariates and used for inverse probability of treatment weighting. Cox proportional hazards regression was conducted using the weighted cohort to determine the survival and major adverse cardiovascular event (MACE)-free survival of EVAR relative to OSR for rAAA up to 10 years after repair. RESULTS: A total of 2692 rAAA (261 EVAR [10%] and 2431 OSR [90%]) repairs were recorded from April 1, 2003, to March 31, 2016. Mean follow-up for the entire cohort was 3.4 years (standard deviation [SD], 3.9 years), with a maximum follow-up of 14.0 years. OSR patients were followed for a mean of 3.5 years (SD, 4.0 years) and maximum of 14.0 years, and EVAR patients were followed for a mean of 2.7 years (SD, 2.7 years) and a maximum of 11.4 years. Median survival was 2.7 years overall, and 2.5 and 3.7 years for OSR and EVAR patients, respectively. There were no significant baseline differences between EVAR and OSR patients after inverse probability of treatment weighting. EVAR patients were at lower hazard for all-cause mortality (hazard ratio, 0.49; 95% confidence interval, 0.37-0.65; P < .01), and MACE (hazard ratio, 0.51, 95% confidence interval, 0.40-0.66; P < .01) within 30 days of repair. There were no statistically significant differences between EVAR and OSR in the hazard for all-cause mortality or MACE from 30 days to 5 years, and 5 to 10 years. Despite this, the upfront mortality and MACE benefits of EVAR persisted for more than 4.5 years after repair. CONCLUSIONS: This population-based cohort study using administrative data from Ontario, Canada, demonstrated lower hazards for all-cause mortality and MACE within 30 days of operation in favor of EVAR, but no differences in the mid- or longer-term results. More work is needed to understand and improve the long-term outcomes of ruptured endovascular aortic aneurysm repair and ruptured open surgical repair.
引用
- Salata K, Hussain MA, de Mestral C, et al. Population-based long-term outcomes of open versus endovascular aortic repair of ruptured abdominal aortic aneurysms. J Vasc Surg. 2020. PMID: 32085959. doi:10.1016/j.jvs.2019.06.212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。